Comparative Preclinical Pharmacokinetics and Bioavailability of Antidepressant GSB-106 Tablet Form

G B Kolyvanov; V P Zherdev; O G Gribakina; P O Bochkov; R V Shevchenko; A A Litvin; E V Blynskaya; V V Bueva

doi:10.1007/s10517-019-04587-w

Comparative Preclinical Pharmacokinetics and Bioavailability of Antidepressant GSB-106 Tablet Form

Bull Exp Biol Med. 2019 Sep;167(5):637-640. doi: 10.1007/s10517-019-04587-w. Epub 2019 Oct 17.

Authors

G B Kolyvanov¹, V P Zherdev², O G Gribakina², P O Bochkov², R V Shevchenko², A A Litvin², E V Blynskaya³, V V Bueva³

Affiliations

¹ Laboratory of Pharmacokinetics, Moscow, Russia. litbiopharm@yandex.ru.
² Laboratory of Pharmacokinetics, Moscow, Russia.
³ Laboratory of Finished Dosage Forms, V. V. Zakusov Research Institute of Pharmacology, Russian Academy of Medical Sciences, Moscow, Russia.

PMID: 31625065
DOI: 10.1007/s10517-019-04587-w

Abstract

Pharmacokinetics and relative bioavailability of antidepressant GSB-106 (hexamethylendiamide bis-(N-monosuccinyl-L-seryl-L-lysine) were determined in rabbits after single oral administration of the pharmaceutical substance and tablet mass. GSB-106 concentrations in the blood plasma were determined by HPLC-mass spectrometry. Relative bioavailability of GSB-106 tablet form was 160.79±24.33%.

Keywords: GSB-106; HPLC-MS; antidepressant; preclinical pharmacokinetics.

Publication types

Comparative Study

MeSH terms

Administration, Oral
Animals
Antidepressive Agents / blood
Antidepressive Agents / pharmacokinetics*
Area Under Curve
Biological Availability
Dipeptides / blood
Dipeptides / pharmacokinetics*
Drug Evaluation, Preclinical
Male
Rabbits
Tablets

Substances

Antidepressive Agents
Dipeptides
Tablets
bis-(N-monosuccinyl-l-seryl-l-lysine)hexamethylenediamide